Project Grant R01CA304543
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $191,700.00 to Cedars-Sinai Medical Center to conduct research on the etiology and tumor characteristics of early-onset pancreatic cancer. The research aims to identify modifiable risk factors associated with the development of early-onset pancreatic cancer and characterize the clinicopathological and molecular features of tumors in affected patients. The award period runs from...
- This $729,690 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports metabolic intervention research to halt pancreatic cancer at Cedars-Sinai Medical Center in West Hollywood, California. The project will run from November 1, 2024 to October 31, 2027, investigating innovative approaches to disease prevention, diagnosis, treatment, and management of pancreatic cancer. As a prominent research institution,...
- The National Cancer Institute (NCI) has awarded a $572,490 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The project, titled "PILLAR: Multi-Modal Imaging AI Models for Breast Cancer Risk", aims to develop an AI-powered tool to predict breast cancer risk using longitudinal data from mammograms, tomosynthesis, and MRI scans. The goal is to create more accurate cancer risk...
- This $681,215 federal Project Grant was awarded on September 1, 2025 by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to New York University (NYU) to develop AI-powered diagnostic tools for early prostate cancer detection. The project aims to leverage machine learning models to infer the presence of clinically significant prostate cancer using a minimal amount of degraded MRI data, in order to enable widespread, cost-effective population-level disease...
- The National Cancer Institute (NCI) awarded a $700,611 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL)," aims to determine the benefits and barriers to clinical adoption of AI systems for improving melanoma detection and reducing the number of unnecessary biopsies. The project...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) in the amount of $399,112 will be used by Imvaria Inc. to adapt its fully automated, AI-powered "DigitalBX" diagnostic tool for analyzing chest CT scans to detect pulmonary nodules suspicious of lung cancer. The goal is to provide an end-to-end automated diagnostic solution implemented as a secure cloud-based application that is fully reimbursable, alleviating the cost...
- This $1,686,258 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Onc.ai, Inc. aims to further develop and validate a deep learning radiomics biomarker for improved early response assessment in metastatic cancer therapy trials. The proposed approach uses deep learning models on CT scans at baseline and follow-up time points to generate a continuous "Serial CT Response Score" that can more accurately predict overall...
- This federal Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $739,640 to the Fred Hutchinson Cancer Center to develop methods for advancing the early detection of pancreatic ductal adenocarcinoma (PDAC) by leveraging electronic medical records (EMR) data. The key objectives of the project are to: Better define the at-risk population for PDAC beyond just new-onset diabetes, including those with new-onset prediabetes and...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has awarded a $693,156 Project Grant (CFDA 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health) to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop artificial intelligence (AI) algorithms for predicting prognosis and optimizing treatment selection for cutaneous squamous cell carcinoma (CSCC), a highly prevalent form of skin cancer. The project aims to train and validate AI...
The Cedars-Sinai Medical Center was awarded a $523,670 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop an artificial intelligence (AI) model for the early detection of pancreatic tumors using abdominal computed tomography (CT) scans. The key objectives are to: 1) Analyze CT image texture variations in different regions of the pancreas to enhance tumor detection, 2) Integrate distinctive morphological features of the pancreas, surrounding tissues, and liver that indicate the presence of cancer, and 3) Incorporate non-imaging factors associated with pancreatic cancer. The project aims to improve early-stage pancreatic cancer detection to increase treatment options and survival rates. The grant was awarded on September 12, 2025 with an ultimate completion date of August 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $523.7k | 9/11/25 |